Fibroblast growth factor 21 analogues in the FDA pipeline: Hope for metabolic dysfunction-associated steatotic liver disease therapy after resmetirom

Hepatobiliary & Pancreatic Diseases International · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles